Drugs / 25-HYDROXYERGOCALCIFEROL-
25-HYDROXYERGOCALCIFEROL-
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT05306704 Comparator | Feb 2019 → Jan 2022 | HIV infectious disease, vitamin D deficiency | University of the Punjab | Completed | No outcome recorded |
| — | NCT03334136 Comparator | Nov 2017 → May 2019 | psoriasis, vitamin D deficiency | University Hospital of North Norway | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 25-HYDROXYERGOCALCIFEROL- | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095206 ↗ |
| Known as | 25-hydroxycalciferol | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095206 ↗ |
| Known as | 25-Hydroxyvitamin D | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05306704 ↗ |
| Known as | 25-hydroxyvitamin d 2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095206 ↗ |
| Known as | Ercalcidiol | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095206 ↗ |
| Modality | Small molecule | — CHEMBL5095206 ↗ |
| Route | Oral | “Capsules containing 20 000 IU 25-hydroxyvitamin D given orally” NCT03334136 ↗ |